Cytokines in clinical cancer immunotherapy View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2018-11-09

AUTHORS

Pedro Berraondo, Miguel F. Sanmamed, María C Ochoa, Iñaki Etxeberria, Maria A. Aznar, José Luis Pérez-Gracia, María E. Rodríguez-Ruiz, Mariano Ponz-Sarvise, Eduardo Castañón, Ignacio Melero

ABSTRACT

Cytokines are soluble proteins that mediate cell-to-cell communication. Based on the discovery of the potent anti-tumour activities of several pro-inflammatory cytokines in animal models, clinical research led to the approval of recombinant interferon-alpha and interleukin-2 for the treatment of several malignancies, even if efficacy was only modest. These early milestones in immunotherapy have been followed by the recent addition to clinical practice of antibodies that inhibit immune checkpoints, as well as chimeric antigen receptor T cells. A renewed interest in the anti-tumour properties of cytokines has led to an exponential increase in the number of clinical trials that explore the safety and efficacy of cytokine-based drugs, not only as single agents, but also in combination with other immunomodulatory drugs. These second-generation drugs under clinical development include known molecules with novel mechanisms of action, new targets, and fusion proteins that increase half-life and target cytokine activity to the tumour microenvironment or to the desired effector immune cells. In addition, the detrimental activity of immunosuppressive cytokines can be blocked by antagonistic antibodies, small molecules, cytokine traps or siRNAs. In this review, we provide an overview of the novel trends in the cytokine immunotherapy field that are yielding therapeutic agents for clinical trials. More... »

PAGES

6-15

References to SciGraph publications

Journal

TITLE

British Journal of Cancer

ISSUE

1

VOLUME

120

Identifiers

URI

http://scigraph.springernature.com/pub.10.1038/s41416-018-0328-y

DOI

http://dx.doi.org/10.1038/s41416-018-0328-y

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1109786690

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/30413827


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1107", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Immunology", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antibodies, Monoclonal", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cytokines", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Immunotherapy", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Immunotherapy, Adoptive", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Interferon-alpha", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Interleukin-2", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Receptors, Chimeric Antigen", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Tumor Microenvironment", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Centro de Investigaci\u00f3n Biom\u00e9dica en Red de C\u00e1ncer (CIBERONC), Pamplona, Spain", 
          "id": "http://www.grid.ac/institutes/grid.510933.d", 
          "name": [
            "Immunology and Immunotherapy Program, Center for Applied Medical Research, CIMA, University of Navarra, Pamplona, Spain", 
            "Navarra Institute for Health Research (IDISNA), Pamplona, Spain", 
            "Centro de Investigaci\u00f3n Biom\u00e9dica en Red de C\u00e1ncer (CIBERONC), Pamplona, Spain"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Berraondo", 
        "givenName": "Pedro", 
        "id": "sg:person.01216060420.33", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01216060420.33"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Oncology and immunology, Cl\u00ednica Universidad de Navarra, Pamplona, Spain", 
          "id": "http://www.grid.ac/institutes/grid.411730.0", 
          "name": [
            "Immunology and Immunotherapy Program, Center for Applied Medical Research, CIMA, University of Navarra, Pamplona, Spain", 
            "Navarra Institute for Health Research (IDISNA), Pamplona, Spain", 
            "Centro de Investigaci\u00f3n Biom\u00e9dica en Red de C\u00e1ncer (CIBERONC), Pamplona, Spain", 
            "Department of Oncology and immunology, Cl\u00ednica Universidad de Navarra, Pamplona, Spain"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Sanmamed", 
        "givenName": "Miguel F.", 
        "id": "sg:person.0734047703.82", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0734047703.82"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Centro de Investigaci\u00f3n Biom\u00e9dica en Red de C\u00e1ncer (CIBERONC), Pamplona, Spain", 
          "id": "http://www.grid.ac/institutes/grid.510933.d", 
          "name": [
            "Immunology and Immunotherapy Program, Center for Applied Medical Research, CIMA, University of Navarra, Pamplona, Spain", 
            "Navarra Institute for Health Research (IDISNA), Pamplona, Spain", 
            "Centro de Investigaci\u00f3n Biom\u00e9dica en Red de C\u00e1ncer (CIBERONC), Pamplona, Spain"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Ochoa", 
        "givenName": "Mar\u00eda C", 
        "id": "sg:person.01046650520.81", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01046650520.81"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Centro de Investigaci\u00f3n Biom\u00e9dica en Red de C\u00e1ncer (CIBERONC), Pamplona, Spain", 
          "id": "http://www.grid.ac/institutes/grid.510933.d", 
          "name": [
            "Immunology and Immunotherapy Program, Center for Applied Medical Research, CIMA, University of Navarra, Pamplona, Spain", 
            "Navarra Institute for Health Research (IDISNA), Pamplona, Spain", 
            "Centro de Investigaci\u00f3n Biom\u00e9dica en Red de C\u00e1ncer (CIBERONC), Pamplona, Spain"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Etxeberria", 
        "givenName": "I\u00f1aki", 
        "id": "sg:person.01153434207.00", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01153434207.00"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Centro de Investigaci\u00f3n Biom\u00e9dica en Red de C\u00e1ncer (CIBERONC), Pamplona, Spain", 
          "id": "http://www.grid.ac/institutes/grid.510933.d", 
          "name": [
            "Immunology and Immunotherapy Program, Center for Applied Medical Research, CIMA, University of Navarra, Pamplona, Spain", 
            "Navarra Institute for Health Research (IDISNA), Pamplona, Spain", 
            "Centro de Investigaci\u00f3n Biom\u00e9dica en Red de C\u00e1ncer (CIBERONC), Pamplona, Spain"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Aznar", 
        "givenName": "Maria A.", 
        "id": "sg:person.01125273021.49", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01125273021.49"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Oncology and immunology, Cl\u00ednica Universidad de Navarra, Pamplona, Spain", 
          "id": "http://www.grid.ac/institutes/grid.411730.0", 
          "name": [
            "Immunology and Immunotherapy Program, Center for Applied Medical Research, CIMA, University of Navarra, Pamplona, Spain", 
            "Navarra Institute for Health Research (IDISNA), Pamplona, Spain", 
            "Centro de Investigaci\u00f3n Biom\u00e9dica en Red de C\u00e1ncer (CIBERONC), Pamplona, Spain", 
            "Department of Oncology and immunology, Cl\u00ednica Universidad de Navarra, Pamplona, Spain"
          ], 
          "type": "Organization"
        }, 
        "familyName": "P\u00e9rez-Gracia", 
        "givenName": "Jos\u00e9 Luis", 
        "id": "sg:person.01232371705.32", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01232371705.32"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Oncology and immunology, Cl\u00ednica Universidad de Navarra, Pamplona, Spain", 
          "id": "http://www.grid.ac/institutes/grid.411730.0", 
          "name": [
            "Immunology and Immunotherapy Program, Center for Applied Medical Research, CIMA, University of Navarra, Pamplona, Spain", 
            "Navarra Institute for Health Research (IDISNA), Pamplona, Spain", 
            "Centro de Investigaci\u00f3n Biom\u00e9dica en Red de C\u00e1ncer (CIBERONC), Pamplona, Spain", 
            "Department of Oncology and immunology, Cl\u00ednica Universidad de Navarra, Pamplona, Spain"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Rodr\u00edguez-Ruiz", 
        "givenName": "Mar\u00eda E.", 
        "id": "sg:person.01337107417.01", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01337107417.01"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Oncology and immunology, Cl\u00ednica Universidad de Navarra, Pamplona, Spain", 
          "id": "http://www.grid.ac/institutes/grid.411730.0", 
          "name": [
            "Immunology and Immunotherapy Program, Center for Applied Medical Research, CIMA, University of Navarra, Pamplona, Spain", 
            "Navarra Institute for Health Research (IDISNA), Pamplona, Spain", 
            "Centro de Investigaci\u00f3n Biom\u00e9dica en Red de C\u00e1ncer (CIBERONC), Pamplona, Spain", 
            "Department of Oncology and immunology, Cl\u00ednica Universidad de Navarra, Pamplona, Spain"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Ponz-Sarvise", 
        "givenName": "Mariano", 
        "id": "sg:person.0617344125.68", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0617344125.68"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Oncology and immunology, Cl\u00ednica Universidad de Navarra, Pamplona, Spain", 
          "id": "http://www.grid.ac/institutes/grid.411730.0", 
          "name": [
            "Immunology and Immunotherapy Program, Center for Applied Medical Research, CIMA, University of Navarra, Pamplona, Spain", 
            "Navarra Institute for Health Research (IDISNA), Pamplona, Spain", 
            "Centro de Investigaci\u00f3n Biom\u00e9dica en Red de C\u00e1ncer (CIBERONC), Pamplona, Spain", 
            "Department of Oncology and immunology, Cl\u00ednica Universidad de Navarra, Pamplona, Spain"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Casta\u00f1\u00f3n", 
        "givenName": "Eduardo", 
        "id": "sg:person.0577445167.66", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0577445167.66"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Oncology and immunology, Cl\u00ednica Universidad de Navarra, Pamplona, Spain", 
          "id": "http://www.grid.ac/institutes/grid.411730.0", 
          "name": [
            "Immunology and Immunotherapy Program, Center for Applied Medical Research, CIMA, University of Navarra, Pamplona, Spain", 
            "Navarra Institute for Health Research (IDISNA), Pamplona, Spain", 
            "Centro de Investigaci\u00f3n Biom\u00e9dica en Red de C\u00e1ncer (CIBERONC), Pamplona, Spain", 
            "Department of Oncology and immunology, Cl\u00ednica Universidad de Navarra, Pamplona, Spain"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Melero", 
        "givenName": "Ignacio", 
        "id": "sg:person.0777142412.98", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0777142412.98"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1038/cgt.2009.45", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1016041053", 
          "https://doi.org/10.1038/cgt.2009.45"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/nrc3973", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1050903209", 
          "https://doi.org/10.1038/nrc3973"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/s41467-017-02358-7", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1099865047", 
          "https://doi.org/10.1038/s41467-017-02358-7"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/nature21349", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1000326025", 
          "https://doi.org/10.1038/nature21349"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s12016-015-8468-9", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1011360019", 
          "https://doi.org/10.1007/s12016-015-8468-9"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/377348a0", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1032084537", 
          "https://doi.org/10.1038/377348a0"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/nrd1175", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1034371730", 
          "https://doi.org/10.1038/nrd1175"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/sj.bjc.6600479", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1021994551", 
          "https://doi.org/10.1038/sj.bjc.6600479"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/nrd3810", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1011707149", 
          "https://doi.org/10.1038/nrd3810"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/nri2097", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1013715729", 
          "https://doi.org/10.1038/nri2097"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/nm.3337", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1052264983", 
          "https://doi.org/10.1038/nm.3337"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/nature25492", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1101019927", 
          "https://doi.org/10.1038/nature25492"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/2051-1426-2-s3-p122", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1015101862", 
          "https://doi.org/10.1186/2051-1426-2-s3-p122"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/nature07205", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1024729982", 
          "https://doi.org/10.1038/nature07205"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2018-11-09", 
    "datePublishedReg": "2018-11-09", 
    "description": "Cytokines are soluble proteins that mediate cell-to-cell communication. Based on the discovery of the potent anti-tumour activities of several pro-inflammatory cytokines in animal models, clinical research led to the approval of recombinant interferon-alpha and interleukin-2 for the treatment of several malignancies, even if efficacy was only modest. These early milestones in immunotherapy have been followed by the recent addition to clinical practice of antibodies that inhibit immune checkpoints, as well as chimeric antigen receptor T cells. A renewed interest in the anti-tumour properties of cytokines has led to an exponential increase in the number of clinical trials that explore the safety and efficacy of cytokine-based drugs, not only as single agents, but also in combination with other immunomodulatory drugs. These second-generation drugs under clinical development include known molecules with novel mechanisms of action, new targets, and fusion proteins that increase half-life and target cytokine activity to the tumour microenvironment or to the desired effector immune cells. In addition, the detrimental activity of immunosuppressive cytokines can be blocked by antagonistic antibodies, small molecules, cytokine traps or siRNAs. In this review, we provide an overview of the novel trends in the cytokine immunotherapy field that are yielding therapeutic agents for clinical trials.", 
    "genre": "article", 
    "id": "sg:pub.10.1038/s41416-018-0328-y", 
    "isAccessibleForFree": true, 
    "isFundedItemOf": [
      {
        "id": "sg:grant.8097974", 
        "type": "MonetaryGrant"
      }, 
      {
        "id": "sg:grant.3938445", 
        "type": "MonetaryGrant"
      }, 
      {
        "id": "sg:grant.8098648", 
        "type": "MonetaryGrant"
      }, 
      {
        "id": "sg:grant.8098509", 
        "type": "MonetaryGrant"
      }
    ], 
    "isPartOf": [
      {
        "id": "sg:journal.1017082", 
        "issn": [
          "0007-0920", 
          "1532-1827"
        ], 
        "name": "British Journal of Cancer", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "1", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "120"
      }
    ], 
    "keywords": [
      "clinical trials", 
      "chimeric antigen receptor T cells", 
      "antigen receptor T cells", 
      "potent anti-tumor activity", 
      "pro-inflammatory cytokines", 
      "receptor T cells", 
      "effector immune cells", 
      "clinical cancer immunotherapy", 
      "second-generation drugs", 
      "anti-tumor activity", 
      "anti-tumor properties", 
      "immunosuppressive cytokines", 
      "immunotherapy field", 
      "immune checkpoints", 
      "immunomodulatory drugs", 
      "cancer immunotherapy", 
      "immune cells", 
      "interleukin-2", 
      "T cells", 
      "animal models", 
      "clinical development", 
      "clinical practice", 
      "single agent", 
      "cytokine activity", 
      "antagonistic antibodies", 
      "cytokines", 
      "tumor microenvironment", 
      "clinical research", 
      "therapeutic agents", 
      "new targets", 
      "immunotherapy", 
      "drugs", 
      "trials", 
      "antibodies", 
      "efficacy", 
      "novel mechanism", 
      "cells", 
      "detrimental activities", 
      "malignancy", 
      "fusion protein", 
      "agents", 
      "cell communication", 
      "activity", 
      "treatment", 
      "protein", 
      "approval", 
      "microenvironment", 
      "recent addition", 
      "safety", 
      "early milestones", 
      "review", 
      "small molecules", 
      "siRNAs", 
      "target", 
      "addition", 
      "action", 
      "checkpoint", 
      "soluble protein", 
      "increase", 
      "mechanism", 
      "practice", 
      "exponential increase", 
      "combination", 
      "molecules", 
      "milestones", 
      "development", 
      "number", 
      "discovery", 
      "novel trends", 
      "overview", 
      "trends", 
      "research", 
      "model", 
      "interest", 
      "communication", 
      "properties", 
      "field", 
      "traps"
    ], 
    "name": "Cytokines in clinical cancer immunotherapy", 
    "pagination": "6-15", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1109786690"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1038/s41416-018-0328-y"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "30413827"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1038/s41416-018-0328-y", 
      "https://app.dimensions.ai/details/publication/pub.1109786690"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-12-01T06:37", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20221201/entities/gbq_results/article/article_763.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1038/s41416-018-0328-y"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1038/s41416-018-0328-y'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1038/s41416-018-0328-y'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1038/s41416-018-0328-y'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1038/s41416-018-0328-y'


 

This table displays all metadata directly associated to this object as RDF triples.

314 TRIPLES      21 PREDICATES      127 URIs      105 LITERALS      17 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1038/s41416-018-0328-y schema:about N0e087e082752450eaa070c37942241a9
2 N1d5636de271f46d1854fd82a90b939e1
3 N436a6aacd2d446adb7fd692bb1d8823c
4 N56b19eb0d5fa44abaef3812087c70b1c
5 N998ca32ff6694dc0a10cb70c1031490b
6 Nb04111be5e9b408f8eed3d234bad455d
7 Nca4f1e6ca74c405c981f95781f5e92b7
8 Ne29d345089254e17a5828003604a162f
9 Nfcc1ab0fca6741879ebf64c2b878e101
10 Nffcfe994dbeb49058fba06b739ed387b
11 anzsrc-for:11
12 anzsrc-for:1107
13 schema:author N305d2f81350e45d988d01370112ed8d8
14 schema:citation sg:pub.10.1007/s12016-015-8468-9
15 sg:pub.10.1038/377348a0
16 sg:pub.10.1038/cgt.2009.45
17 sg:pub.10.1038/nature07205
18 sg:pub.10.1038/nature21349
19 sg:pub.10.1038/nature25492
20 sg:pub.10.1038/nm.3337
21 sg:pub.10.1038/nrc3973
22 sg:pub.10.1038/nrd1175
23 sg:pub.10.1038/nrd3810
24 sg:pub.10.1038/nri2097
25 sg:pub.10.1038/s41467-017-02358-7
26 sg:pub.10.1038/sj.bjc.6600479
27 sg:pub.10.1186/2051-1426-2-s3-p122
28 schema:datePublished 2018-11-09
29 schema:datePublishedReg 2018-11-09
30 schema:description Cytokines are soluble proteins that mediate cell-to-cell communication. Based on the discovery of the potent anti-tumour activities of several pro-inflammatory cytokines in animal models, clinical research led to the approval of recombinant interferon-alpha and interleukin-2 for the treatment of several malignancies, even if efficacy was only modest. These early milestones in immunotherapy have been followed by the recent addition to clinical practice of antibodies that inhibit immune checkpoints, as well as chimeric antigen receptor T cells. A renewed interest in the anti-tumour properties of cytokines has led to an exponential increase in the number of clinical trials that explore the safety and efficacy of cytokine-based drugs, not only as single agents, but also in combination with other immunomodulatory drugs. These second-generation drugs under clinical development include known molecules with novel mechanisms of action, new targets, and fusion proteins that increase half-life and target cytokine activity to the tumour microenvironment or to the desired effector immune cells. In addition, the detrimental activity of immunosuppressive cytokines can be blocked by antagonistic antibodies, small molecules, cytokine traps or siRNAs. In this review, we provide an overview of the novel trends in the cytokine immunotherapy field that are yielding therapeutic agents for clinical trials.
31 schema:genre article
32 schema:isAccessibleForFree true
33 schema:isPartOf N176ec28df7194f28aad72629046c85c3
34 N1e9206d86f684fa98bd08c1315419051
35 sg:journal.1017082
36 schema:keywords T cells
37 action
38 activity
39 addition
40 agents
41 animal models
42 antagonistic antibodies
43 anti-tumor activity
44 anti-tumor properties
45 antibodies
46 antigen receptor T cells
47 approval
48 cancer immunotherapy
49 cell communication
50 cells
51 checkpoint
52 chimeric antigen receptor T cells
53 clinical cancer immunotherapy
54 clinical development
55 clinical practice
56 clinical research
57 clinical trials
58 combination
59 communication
60 cytokine activity
61 cytokines
62 detrimental activities
63 development
64 discovery
65 drugs
66 early milestones
67 effector immune cells
68 efficacy
69 exponential increase
70 field
71 fusion protein
72 immune cells
73 immune checkpoints
74 immunomodulatory drugs
75 immunosuppressive cytokines
76 immunotherapy
77 immunotherapy field
78 increase
79 interest
80 interleukin-2
81 malignancy
82 mechanism
83 microenvironment
84 milestones
85 model
86 molecules
87 new targets
88 novel mechanism
89 novel trends
90 number
91 overview
92 potent anti-tumor activity
93 practice
94 pro-inflammatory cytokines
95 properties
96 protein
97 recent addition
98 receptor T cells
99 research
100 review
101 safety
102 second-generation drugs
103 siRNAs
104 single agent
105 small molecules
106 soluble protein
107 target
108 therapeutic agents
109 traps
110 treatment
111 trends
112 trials
113 tumor microenvironment
114 schema:name Cytokines in clinical cancer immunotherapy
115 schema:pagination 6-15
116 schema:productId N179ab182c2814d5eb422b9a6fe67e3ff
117 N7f945be9d2cd43069e09872bbab65151
118 Nc6a5b5a910ae457f98af3720111d1552
119 schema:sameAs https://app.dimensions.ai/details/publication/pub.1109786690
120 https://doi.org/10.1038/s41416-018-0328-y
121 schema:sdDatePublished 2022-12-01T06:37
122 schema:sdLicense https://scigraph.springernature.com/explorer/license/
123 schema:sdPublisher N8824b916388649e9a727905b204abcad
124 schema:url https://doi.org/10.1038/s41416-018-0328-y
125 sgo:license sg:explorer/license/
126 sgo:sdDataset articles
127 rdf:type schema:ScholarlyArticle
128 N07feb1db281248749046624b73fe0558 rdf:first sg:person.01232371705.32
129 rdf:rest N83be44d16d754714a208e1e77af50b2f
130 N0e087e082752450eaa070c37942241a9 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
131 schema:name Interferon-alpha
132 rdf:type schema:DefinedTerm
133 N176ec28df7194f28aad72629046c85c3 schema:issueNumber 1
134 rdf:type schema:PublicationIssue
135 N179ab182c2814d5eb422b9a6fe67e3ff schema:name dimensions_id
136 schema:value pub.1109786690
137 rdf:type schema:PropertyValue
138 N1d5636de271f46d1854fd82a90b939e1 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
139 schema:name Receptors, Chimeric Antigen
140 rdf:type schema:DefinedTerm
141 N1e9206d86f684fa98bd08c1315419051 schema:volumeNumber 120
142 rdf:type schema:PublicationVolume
143 N305d2f81350e45d988d01370112ed8d8 rdf:first sg:person.01216060420.33
144 rdf:rest N7fc680f8f1a24551b7ece481842d765f
145 N436a6aacd2d446adb7fd692bb1d8823c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
146 schema:name Immunotherapy
147 rdf:type schema:DefinedTerm
148 N4a87e7fb078544ab87e4b22c8f615130 rdf:first sg:person.0617344125.68
149 rdf:rest N5da26ade0edf4455b09f6dac7aad6c24
150 N56b19eb0d5fa44abaef3812087c70b1c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
151 schema:name Immunotherapy, Adoptive
152 rdf:type schema:DefinedTerm
153 N5da26ade0edf4455b09f6dac7aad6c24 rdf:first sg:person.0577445167.66
154 rdf:rest N8073fc054a1b47ab8c04ae4274816bcc
155 N7f945be9d2cd43069e09872bbab65151 schema:name pubmed_id
156 schema:value 30413827
157 rdf:type schema:PropertyValue
158 N7fc680f8f1a24551b7ece481842d765f rdf:first sg:person.0734047703.82
159 rdf:rest Nc01b498c6008447cbddf0d1eb3c7e43b
160 N8073fc054a1b47ab8c04ae4274816bcc rdf:first sg:person.0777142412.98
161 rdf:rest rdf:nil
162 N83be44d16d754714a208e1e77af50b2f rdf:first sg:person.01337107417.01
163 rdf:rest N4a87e7fb078544ab87e4b22c8f615130
164 N8824b916388649e9a727905b204abcad schema:name Springer Nature - SN SciGraph project
165 rdf:type schema:Organization
166 N88a7396387064674b58e408123173342 rdf:first sg:person.01125273021.49
167 rdf:rest N07feb1db281248749046624b73fe0558
168 N998ca32ff6694dc0a10cb70c1031490b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
169 schema:name Antibodies, Monoclonal
170 rdf:type schema:DefinedTerm
171 Nb04111be5e9b408f8eed3d234bad455d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
172 schema:name Cytokines
173 rdf:type schema:DefinedTerm
174 Nb346871a859847d1b85f344ca2a36660 rdf:first sg:person.01153434207.00
175 rdf:rest N88a7396387064674b58e408123173342
176 Nc01b498c6008447cbddf0d1eb3c7e43b rdf:first sg:person.01046650520.81
177 rdf:rest Nb346871a859847d1b85f344ca2a36660
178 Nc6a5b5a910ae457f98af3720111d1552 schema:name doi
179 schema:value 10.1038/s41416-018-0328-y
180 rdf:type schema:PropertyValue
181 Nca4f1e6ca74c405c981f95781f5e92b7 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
182 schema:name Interleukin-2
183 rdf:type schema:DefinedTerm
184 Ne29d345089254e17a5828003604a162f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
185 schema:name Tumor Microenvironment
186 rdf:type schema:DefinedTerm
187 Nfcc1ab0fca6741879ebf64c2b878e101 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
188 schema:name Humans
189 rdf:type schema:DefinedTerm
190 Nffcfe994dbeb49058fba06b739ed387b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
191 schema:name Neoplasms
192 rdf:type schema:DefinedTerm
193 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
194 schema:name Medical and Health Sciences
195 rdf:type schema:DefinedTerm
196 anzsrc-for:1107 schema:inDefinedTermSet anzsrc-for:
197 schema:name Immunology
198 rdf:type schema:DefinedTerm
199 sg:grant.3938445 http://pending.schema.org/fundedItem sg:pub.10.1038/s41416-018-0328-y
200 rdf:type schema:MonetaryGrant
201 sg:grant.8097974 http://pending.schema.org/fundedItem sg:pub.10.1038/s41416-018-0328-y
202 rdf:type schema:MonetaryGrant
203 sg:grant.8098509 http://pending.schema.org/fundedItem sg:pub.10.1038/s41416-018-0328-y
204 rdf:type schema:MonetaryGrant
205 sg:grant.8098648 http://pending.schema.org/fundedItem sg:pub.10.1038/s41416-018-0328-y
206 rdf:type schema:MonetaryGrant
207 sg:journal.1017082 schema:issn 0007-0920
208 1532-1827
209 schema:name British Journal of Cancer
210 schema:publisher Springer Nature
211 rdf:type schema:Periodical
212 sg:person.01046650520.81 schema:affiliation grid-institutes:grid.510933.d
213 schema:familyName Ochoa
214 schema:givenName María C
215 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01046650520.81
216 rdf:type schema:Person
217 sg:person.01125273021.49 schema:affiliation grid-institutes:grid.510933.d
218 schema:familyName Aznar
219 schema:givenName Maria A.
220 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01125273021.49
221 rdf:type schema:Person
222 sg:person.01153434207.00 schema:affiliation grid-institutes:grid.510933.d
223 schema:familyName Etxeberria
224 schema:givenName Iñaki
225 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01153434207.00
226 rdf:type schema:Person
227 sg:person.01216060420.33 schema:affiliation grid-institutes:grid.510933.d
228 schema:familyName Berraondo
229 schema:givenName Pedro
230 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01216060420.33
231 rdf:type schema:Person
232 sg:person.01232371705.32 schema:affiliation grid-institutes:grid.411730.0
233 schema:familyName Pérez-Gracia
234 schema:givenName José Luis
235 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01232371705.32
236 rdf:type schema:Person
237 sg:person.01337107417.01 schema:affiliation grid-institutes:grid.411730.0
238 schema:familyName Rodríguez-Ruiz
239 schema:givenName María E.
240 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01337107417.01
241 rdf:type schema:Person
242 sg:person.0577445167.66 schema:affiliation grid-institutes:grid.411730.0
243 schema:familyName Castañón
244 schema:givenName Eduardo
245 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0577445167.66
246 rdf:type schema:Person
247 sg:person.0617344125.68 schema:affiliation grid-institutes:grid.411730.0
248 schema:familyName Ponz-Sarvise
249 schema:givenName Mariano
250 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0617344125.68
251 rdf:type schema:Person
252 sg:person.0734047703.82 schema:affiliation grid-institutes:grid.411730.0
253 schema:familyName Sanmamed
254 schema:givenName Miguel F.
255 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0734047703.82
256 rdf:type schema:Person
257 sg:person.0777142412.98 schema:affiliation grid-institutes:grid.411730.0
258 schema:familyName Melero
259 schema:givenName Ignacio
260 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0777142412.98
261 rdf:type schema:Person
262 sg:pub.10.1007/s12016-015-8468-9 schema:sameAs https://app.dimensions.ai/details/publication/pub.1011360019
263 https://doi.org/10.1007/s12016-015-8468-9
264 rdf:type schema:CreativeWork
265 sg:pub.10.1038/377348a0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1032084537
266 https://doi.org/10.1038/377348a0
267 rdf:type schema:CreativeWork
268 sg:pub.10.1038/cgt.2009.45 schema:sameAs https://app.dimensions.ai/details/publication/pub.1016041053
269 https://doi.org/10.1038/cgt.2009.45
270 rdf:type schema:CreativeWork
271 sg:pub.10.1038/nature07205 schema:sameAs https://app.dimensions.ai/details/publication/pub.1024729982
272 https://doi.org/10.1038/nature07205
273 rdf:type schema:CreativeWork
274 sg:pub.10.1038/nature21349 schema:sameAs https://app.dimensions.ai/details/publication/pub.1000326025
275 https://doi.org/10.1038/nature21349
276 rdf:type schema:CreativeWork
277 sg:pub.10.1038/nature25492 schema:sameAs https://app.dimensions.ai/details/publication/pub.1101019927
278 https://doi.org/10.1038/nature25492
279 rdf:type schema:CreativeWork
280 sg:pub.10.1038/nm.3337 schema:sameAs https://app.dimensions.ai/details/publication/pub.1052264983
281 https://doi.org/10.1038/nm.3337
282 rdf:type schema:CreativeWork
283 sg:pub.10.1038/nrc3973 schema:sameAs https://app.dimensions.ai/details/publication/pub.1050903209
284 https://doi.org/10.1038/nrc3973
285 rdf:type schema:CreativeWork
286 sg:pub.10.1038/nrd1175 schema:sameAs https://app.dimensions.ai/details/publication/pub.1034371730
287 https://doi.org/10.1038/nrd1175
288 rdf:type schema:CreativeWork
289 sg:pub.10.1038/nrd3810 schema:sameAs https://app.dimensions.ai/details/publication/pub.1011707149
290 https://doi.org/10.1038/nrd3810
291 rdf:type schema:CreativeWork
292 sg:pub.10.1038/nri2097 schema:sameAs https://app.dimensions.ai/details/publication/pub.1013715729
293 https://doi.org/10.1038/nri2097
294 rdf:type schema:CreativeWork
295 sg:pub.10.1038/s41467-017-02358-7 schema:sameAs https://app.dimensions.ai/details/publication/pub.1099865047
296 https://doi.org/10.1038/s41467-017-02358-7
297 rdf:type schema:CreativeWork
298 sg:pub.10.1038/sj.bjc.6600479 schema:sameAs https://app.dimensions.ai/details/publication/pub.1021994551
299 https://doi.org/10.1038/sj.bjc.6600479
300 rdf:type schema:CreativeWork
301 sg:pub.10.1186/2051-1426-2-s3-p122 schema:sameAs https://app.dimensions.ai/details/publication/pub.1015101862
302 https://doi.org/10.1186/2051-1426-2-s3-p122
303 rdf:type schema:CreativeWork
304 grid-institutes:grid.411730.0 schema:alternateName Department of Oncology and immunology, Clínica Universidad de Navarra, Pamplona, Spain
305 schema:name Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Pamplona, Spain
306 Department of Oncology and immunology, Clínica Universidad de Navarra, Pamplona, Spain
307 Immunology and Immunotherapy Program, Center for Applied Medical Research, CIMA, University of Navarra, Pamplona, Spain
308 Navarra Institute for Health Research (IDISNA), Pamplona, Spain
309 rdf:type schema:Organization
310 grid-institutes:grid.510933.d schema:alternateName Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Pamplona, Spain
311 schema:name Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Pamplona, Spain
312 Immunology and Immunotherapy Program, Center for Applied Medical Research, CIMA, University of Navarra, Pamplona, Spain
313 Navarra Institute for Health Research (IDISNA), Pamplona, Spain
314 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...